Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT05183048
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • [89Zr]Panitumumab Tracer — DRUG
    All patients entered into the study will have \[89Zr\]Panitumumab-PET/MRI imaging.

Study Details

This pilot clinical study will investigate if Zirconium-89 (89Zr) panitumumab- Positron Emission Tomography/ Magnetic Resonance Imaging (PET/MRI) imaging can more accurately determine size and location of primary tumors compared to standard of care Fludeoxyglucose (18F-FDG) -PET/MRI in newly diagnosed patients with head and neck squamous cell carcinoma (HNSCC) who are undergoing surgical resection. This study is for imaging purposes only and is not a treatment study. The results of this study will not change the clinical treatment plan.

Key Dates

Start date
Feb 20, 2023
Status verified
Dec 2025
Primary completion
Feb 29, 2028
Completion
Feb 29, 2028

Study Design

Enrollment
14 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: [89Zr]panitumumab-PET/MRI patients
    All study patients will receive \[89Zr\]Panitumumab-PET/MRI imaging.

Primary Outcome Measure

Image Quality [ Time Frame: 5-9 days prior to surgery ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UABBirminghamAlabama35249
Sebastian Eady
[email protected]
205-966-2636
Suzanne Lapi, PhD (PRINCIPAL_INVESTIGATOR)
Jason Warram, PhD (SUB_INVESTIGATOR)

Find similar trials in Birmingham, AL

By condition
Head and neck cancer
By specialty
OncologyENT
By research site
UAB· Birmingham, AL

Related Studies